(FM) Oncología
Departamento académico
![Foto de (FM) Oncología](/img/uploaded/1575D5546D141A10EB89AE669C8B8533.jpg)
![Foto de University of Texas MD Anderson Cancer Center](/img/noimage_org.png)
University of Texas MD Anderson Cancer Center
Houston, Estados UnidosPublicaciones en colaboración con investigadores/as de University of Texas MD Anderson Cancer Center (59)
2024
-
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
Journal of Clinical Oncology, Vol. 42, Núm. 1, pp. 47-58
-
The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma
Nature Cancer
2023
-
Antibodies against endogenous retroviruses promote lung cancer immunotherapy
Nature, Vol. 616, Núm. 7957, pp. 563-573
-
Body composition and lung cancer-associated cachexia in TRACERx
Nature Medicine, Vol. 29, Núm. 4, pp. 846-858
-
Evolutionary characterization of lung adenocarcinoma morphology in TRACERx
Nature Medicine
-
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
Nature Communications, Vol. 14, Núm. 1
-
Genomic–transcriptomic evolution in lung cancer and metastasis
Nature, Vol. 616, Núm. 7957, pp. 543-552
-
Lung adenocarcinoma promotion by air pollutants
Nature, Vol. 616, Núm. 7955, pp. 159-167
-
Outcomes and endpoints of relevance in gynecologic cancer clinical trials
International Journal of Gynecological Cancer, Vol. 33, Núm. 3, pp. 323-332
-
The evolution of lung cancer and impact of subclonal selection in TRACERx
Nature, Vol. 616, Núm. 7957, pp. 525-533
-
The evolution of non-small cell lung cancer metastases in TRACERx
Nature, Vol. 616, Núm. 7957, pp. 534-542
-
Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA
Nature, Vol. 616, Núm. 7957, pp. 553-562
2022
-
A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer
Nature Cancer, Vol. 3, Núm. 6, pp. 696-709
-
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup
The Lancet Oncology, Vol. 23, Núm. 8, pp. e374-e384
-
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study
The Lancet Oncology, Vol. 23, Núm. 2, pp. 248-258
-
Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitor
European Journal of Cancer, Vol. 174, pp. S116
2021
-
Corrigendum to ‘The forefront of ovarian cancer therapy: update on PARP inhibitors': [Annals of Oncology 31 (2020) 1148–1159] (Annals of Oncology (2020) 31(9) (1148–1159), (S0923753420398914), (10.1016/j.annonc.2020.06.004))
Annals of Oncology
-
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)
Journal of Clinical Oncology, Vol. 39, Núm. 20, pp. 2304-2312
-
Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
The Lancet Diabetes and Endocrinology, Vol. 9, Núm. 8, pp. 491-501
-
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
The Lancet Oncology, Vol. 22, Núm. 6, pp. 779-789